Sensitivity of single-domain versus multiple-domain outcome measures to identify responders in chronic low-back pain: Pooled analysis of 2 placebo-controlled trials of etoricoxib

Mark P. Jensen*, Thomas J. Schnitzer, Hongwei Wang, Steven S. Smugar, Paul M. Peloso, Arnold Gammaitoni

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Objectives: A composite responder index for chronic low-back pain (CLBP) has recently been proposed to evaluate the efficacy of CLBP treatments in clinical trials. We compared the responsiveness of this composite measure with a number of single-item responder definitions. Methods: We pooled data from 2 placebo-controlled studies of etoricoxib in CLBP to evaluate 5 response criteria: 30% pain intensity (PI) reduction; 50% PI reduction; 20mm absolute reduction (100mm PI visual analog scale); patient global assessment of response to therapy (PGART); and the composite criteria of 30% reduction in PI+30% improvement in PGART of disease status+no worsening in function. We used bootstrap analysis and logistic regression to assess the ability to differentiate etoricoxib and placebo, and the k coefficient to assess agreement among the responder criteria. Results: The criterion of a 20mm improvement in PI resulted in the greatest proportion (71.5%) of patients being classified as responders and all criteria separated etoricoxib from placebo (P≤0.0001). PGART had the highest discriminant ability (odds ratio 5.90), and was significantly (P<0.05) more discriminant than the 20mm and ≥30% improvements and the composite criteria. After adjusting for all other measures, only PGART continued to show a significant treatment effect for etoricoxib versus placebo (P=0.0003). Kappa values contrasting the composite criteria and the single-item measures ranged from 0.59 to 0.85. Discussion: These findings do not support the superiority of a composite index over single-item ratings of PI and PGART ratings, but do suggest that PGART ratings may be more responsive to treatment, perhaps because they measure something in addition to change in PI.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalClinical Journal of Pain
Volume28
Issue number1
DOIs
StatePublished - Jan 2012

Keywords

  • Global assessment
  • Low-back pain
  • Responder
  • Response

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Sensitivity of single-domain versus multiple-domain outcome measures to identify responders in chronic low-back pain: Pooled analysis of 2 placebo-controlled trials of etoricoxib'. Together they form a unique fingerprint.

  • Cite this